The AAD is having their annual meeting in San Antonio Texas from February 1-5, 2008. New product announcements are expected at the largest gathering of Dermatologists.
The 67th AAD Annual Meeting was held in San Francisco, CA, March 6-10, 2009
The obsession of Americans to look young drives demand for cosmetic surgery products. US cosmetic surgery products market is projected to reach $3.07 billion by 2012, while the cosmetic surgery procedures market is projected to reach $15.13 billion by 2012.
Artes Medical Announces Completion of Enrollment and Treatment in ArteFill Skin Test Study
Ohio Woman Undergoes Transformation Into Runway-Worthy Modern Mom
"The Feel Good Filler" Delivers Comfort, Affordability, and Immediate Results
ArteFill, the first and only FDA-approved non-resorbable injectable dermal filler, provides patients and doctors with a long-lasting solution for the correction of nasolabial folds, or "smile line" wrinkles.
Through this agreement, Artes Medical’s dedicated sales force will market and sell Elevess, the first FDA-approved HA dermal filler for the temporary correction of facial wrinkles that is formulated with an anesthetic for patient comfort, as well as the company’s flagship product, ArteFill, the first and only FDA-approved non-resorbable wrinkle filler for long-lasting correction of smile line wrinkles
Artes Medical, Inc. (Nasdaq:ARTE), maker of the long-lasting dermal filler ArteFill®, is celebrating women’s changing lives with the ArteFill Face Forward Makeover Contest. Women age 35 and over are invited to submit personal stories about a current or upcoming time of personal change. Four winners, selected by a panel of judges, will be honored with makeovers worth approximately $10,000
This newly published study evaluated five different PMMA products available over the past several years in the U.S. (one product), Europe (one product), Brazil (two products) and Canada (one product) for PMMA microsphere size and morphology using Scanning Electron Microscope (SEM) techniques. Each of the five products was evaluated with respect to PMMA microsphere size, homogeneity and surface characteristics. Results from the comparison show marked differences with respect to PMMA microsphere size and morphology. Products obtained from various markets outside the U.S. over time contained variable PMMA particle sizes with shape and surface irregularities, whereas the U.S. product, ArteFill, demonstrated round, smooth, uniformly sized particles.
The clinical study investigator, Mary Olszewski, DPM, American Board of Podiatric Orthopedic & Primary Podiatric Medicine, reports that she is conducting this study to evaluate ArteFill for the reduction of pain and impact on activity level caused by fat pad loss in the plantar metatarsal area in patients who have pain in their feet and who have failed the use of traditional conservative therapies such as pads, shoe wear, orthotics and /or possible use of other temporary injectable dermal filler materials.
Mr. Abel previously served as Vice President of the Dermatology Business Unit of Biogen Idec, Inc. He also formerly served as Director of Marketing, Botox®, at Allergan, Inc. and prior to that, as a Senior Product Manager in Allergan’s skin care division.
Feedback from both physicians and patients to date has been very positive, with high levels of interest from consumers to participate in the study.
In addition to presentations on ArteFill’s safety, long-term efficacy, and differences among various dermal filler products, leading plastic surgeons had the opportunity to observe ArteFill in action. Dr. Cohen provided a live patient demonstration with ArteFill injections during “The Importance of Non-Surgical Options in Your Practice” session, showcasing ArteFill’s ease of injection, immediate correction and minimal downtime.
Artes Medical reported that dermatologists, plastic surgeons and cosmetic surgeons are actively integrating ArteFill into their practices and estimates that over 7,000 patients have been treated with the enduring solution, ArteFill, since the product launch in February 2007.
Artes Medical, Inc. (Nasdaq:ARTE) a medical technology company whose product ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of “smile line” wrinkles, today reported the launch of its new consumer-oriented website, ArteFill.com.
Mark G. Rubin, MD from the University of California in San Diego presented data from a 5-year study on the product ArteFill during the American Academy of Dermatology 66th Annual Meeting
SAN DIEGO's CONNECT announced the winners of the 2007 Most Innovative New Product (MIP) Awards. Mayor Jerry Sanders opened the Awards presentation, which honor the vision, hard work and perseverance that transform ideas and technologies into products. Artes Medical received the award in the Life Sciences - Medical Products category for ArteFill, the first FDA approved permanent injectable filler for wrinkle correction.
ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of nasolabial fold or "smile line" wrinkles
ArteFill is the first and only FDA-approved non-resorbable injectable dermal filler for the correction of wrinkles known as smile lines or nasolabial folds